Equity Overview
Price & Market Data
Price: $2.85
Daily Change: +$0.03 / 1.05%
Range: $2.80 - $2.90
Market Cap: $282,277,856
Volume: 78,837
Performance Metrics
1 Week: 14.20%
1 Month: -11.34%
3 Months: -8.79%
6 Months: -42.32%
1 Year: -34.82%
YTD: -19.80%
Company Details
Employees: 142
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.